This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Shaocong Mo
Shanghai Medical University: Fudan University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8556-1314
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) misses the opportunity for surgery because it is not detected early. The molecular mechanism of hepatitis B-related liver cancer needs further understanding, and effective diagnostic and prognostic models are in urgent need.
Methods: Expression profiles from the Cancer Genome Atlas (TCGA) Liver Hepatocellular Carcinoma (LIHC), GSE121248, GSE94660 GSE76724 from Gene Expression Omnibus (GEO) database were obtained. Differentially expressed genes (DEGs) between normal and tumor HBV-related HCC samples based on GSE121248 and GSE94660. Gene pairs are generated by comparing the expression levels of every two DEGs. A diagnostic signature of pairs of DEGs was built using cross-validation Lasso and Best Subset Selection regression. Hub genes and significant modules were screened by Cytoscape, and potential drugs were predicted by DGIdb. A prognostic signature was established and xCell and ssGSEA were utilized to reveal the cell composition and cancer hallmarks to get an elucidation for the risk.
Results: 457 DEGs were screened. A powerful diagnostic signature of 2 pairs of DEGs was built and validated in TCGA-LIHC and GEO datasets repeatedly with assured performance. 10 Hub genes were found and fostamatinib was predicted to have potential therapeutic effect on HBV-related HCC. A prognostic signature with good efficiency (Log-rank P value<0.05, AUC=93.1%) were established, with stromal score and several hallmarks related to the risk
Conclusion: Taken together, the study provided sight into the molecular mechanism as well as a novel strategy for the early diagnosis and prognosis for HBV-related HCC.
Keywords
hepatitis B virus, hepatocellular carcinoma, gene pair, signature, diagnosis, prognosis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Apr, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Shaocong Mo
Shanghai Medical University: Fudan University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8556-1314
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Apr, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) misses the opportunity for surgery because it is not detected early. The molecular mechanism of hepatitis B-related liver cancer needs further understanding, and effective diagnostic and prognostic models are in urgent need.
Methods: Expression profiles from the Cancer Genome Atlas (TCGA) Liver Hepatocellular Carcinoma (LIHC), GSE121248, GSE94660 GSE76724 from Gene Expression Omnibus (GEO) database were obtained. Differentially expressed genes (DEGs) between normal and tumor HBV-related HCC samples based on GSE121248 and GSE94660. Gene pairs are generated by comparing the expression levels of every two DEGs. A diagnostic signature of pairs of DEGs was built using cross-validation Lasso and Best Subset Selection regression. Hub genes and significant modules were screened by Cytoscape, and potential drugs were predicted by DGIdb. A prognostic signature was established and xCell and ssGSEA were utilized to reveal the cell composition and cancer hallmarks to get an elucidation for the risk.
Results: 457 DEGs were screened. A powerful diagnostic signature of 2 pairs of DEGs was built and validated in TCGA-LIHC and GEO datasets repeatedly with assured performance. 10 Hub genes were found and fostamatinib was predicted to have potential therapeutic effect on HBV-related HCC. A prognostic signature with good efficiency (Log-rank P value<0.05, AUC=93.1%) were established, with stromal score and several hallmarks related to the risk
Conclusion: Taken together, the study provided sight into the molecular mechanism as well as a novel strategy for the early diagnosis and prognosis for HBV-related HCC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
This is a list of supplementary files associated with this preprint. Click to download.
Loading...